FDA, CMS Reviewers Appraise Cost Effectiveness; ICD Decision Scrutinized
This article was originally published in The Gray Sheet
Executive Summary
Cost-effectiveness analyses represent an opportunity for greater FDA/CMS collaboration when the agencies review device trials for approval or reimbursement decisions, according to FDA Office of Device Evaluation Director Dan Schultz